News | June 10, 2026
GSK bets big on oncology with $10.6 billion Nuvalent acquisition
Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio
Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio
The safety profile was described as manageable, though not without notable toxicities
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer
The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial
The decision clears the drug as a monotherapy for adults with unresectable, locally advanced or metastatic non-small cell lung cancer
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
